# Efficacy and Safety of SHR-1905 Injection in Subjects With Chronic Rhinosinusitis With Nasal Polyps

> **NCT07132827** · PHASE3 · RECRUITING · sponsor: **Guangdong Hengrui Pharmaceutical Co., Ltd** · enrollment: 280 (estimated)

## Conditions studied

- Chronic Rhinosinusitis With Nasal Polyps

## Interventions

- **DRUG:** SHR-1905 Injection
- **DRUG:** SHR-1905 Placebo Injection

## Key facts

- **NCT ID:** NCT07132827
- **Lead sponsor:** Guangdong Hengrui Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-28
- **Primary completion:** 2028-04
- **Final completion:** 2028-04
- **Target enrollment:** 280 (ESTIMATED)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07132827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07132827, "Efficacy and Safety of SHR-1905 Injection in Subjects With Chronic Rhinosinusitis With Nasal Polyps". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07132827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*